Market capitalization | $4.66m |
Enterprise Value | $6.52m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
P/B ratio (TTM) P/B ratio | negative |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-3.99m |
Free Cash Flow (TTM) Free Cash Flow | $-3.47m |
Cash position | $1.64m |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -3.99 -3.99 |
30%
30%
|
EBIT (Operating Income) EBIT | -3.99 -3.99 |
30%
30%
|
Net Profit | -4 -4 |
30%
30%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY.
Head office | United States |
CEO | Bastiaan Baan |
Employees | 4 |
Founded | 2005 |
Website | www.lixte.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.